Navigation Links
WuXi PharmaTech Provides Update of 2011 Financial Guidance, to Present at J.P. Morgan Healthcare Conference
Date:1/9/2012

SHANGHAI, Jan. 9, 2012 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology, and medical-device research and development outsourcing company, with operations in China and the United States, today announced that it will present at the 30th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2012 at 4:30 p.m. Pacific Standard Time and updated its 2011 financial guidance. Based on preliminary, unaudited results, WuXi expects to slightly exceed the top end of its previous guidance for 2011 total net revenues of $402-406 million and to meet the remainder of the 2011 financial guidance found in its third-quarter 2011 earnings release.

WuXi plans to report its audited fourth-quarter and full-year 2011 financial results and to provide 2012 financial guidance in March 2012.

For more information, please contact:

WuXi PharmaTech (Cayman) Inc.
Ronald Aldridge (for investors)
Director of Investor Relations
Tel: +1-201-585-2048
Email: ir@wuxiapptec.com

Stephanie Liu (for the media)
WuXi PharmaTech (Cayman) Inc.
Tel: +86-21-5046-4362
Email: pr@wuxiapptec.com

Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including those with respect to our financial guidance for full-year 2011 and prospects generally, are based on our preliminary unaudited results and are subject to the completion of our 2011 audit. Our actual results and financial condition and other circumstances may differ, possibly materially, from the antic
'/>"/>

SOURCE WuXi PharmaTech
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
2. Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
3. WuXi PharmaTech Included in the Deloitte Technology Fast 500 Asia Pacific 2009 List for the Sixth Consecutive Year
4. WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release
5. WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai
6. WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training
7. WuXi PharmaTech Schedules First-Quarter 2010 Earnings Release
8. WuXi PharmaTech Announces First-Quarter 2010 Results
9. WuXi PharmaTech Appoints Hao Zhou as Chief Financial Officer
10. WuXi PharmaTech Well Positioned to Continue Growing as Independent Company; Will Receive Breakup Fee of $30 million
11. WuXi PharmaTech RESCHEDULES Second-Quarter 2010 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... AUSTIN, Texas , March 4, 2015 /PRNewswire/ ... Phase II pilot study in patients with moderate ... JAMA Dermatology. The open-label Phase II trial evaluated ... Human™ monoclonal antibody that targets interleukin-1 alpha (IL-1a). ... and inflammatory cells present in skin lesions. The ...
(Date:3/4/2015)... , March 4, 2015 UPM Pharmaceuticals, a ... agreement with Sprout Pharmaceuticals to manufacture Flibanserin 100 mg ... to be the first drug approved to treat hypoactive ... female sexual dysfunction. The tablets will be ... Bristol, Tennessee . Dr. ...
(Date:3/4/2015)... March 4, 2015   Mayo Clinic and ... develop the next generation of wearable biosensors designed to ... that this technology will be game-changer. These patch biosensors ... James Levine, M.D., Ph.D. , a Mayo Clinic ... inexpensive, and can be integrated into the care people ...
Breaking Medicine Technology:XBiotech Announces Phase II Psoriasis Study Results in JAMA Dermatology 2UPM Pharmaceuticals to Manufacture Sprout Pharmaceuticals' Flibanserin Tablets 2UPM Pharmaceuticals to Manufacture Sprout Pharmaceuticals' Flibanserin Tablets 3Mayo Clinic and Gentag, Inc. Announce Agreement To Develop Wireless Sensors for Treatment of Obesity and Diabetes 2Mayo Clinic and Gentag, Inc. Announce Agreement To Develop Wireless Sensors for Treatment of Obesity and Diabetes 3
(Date:3/4/2015)... Information Innovators Inc . (Triple-i) is honored ... the company as Chief Technology Officer. Mr. Dvorak will ... company, including customer-centric strategies and initiatives, and promoting continuous ... as a technology executive and visionary. Prior to joining ... including oversight of enterprise data management, analytic software development, ...
(Date:3/4/2015)... 2015 The Alliance for Regenerative ... its upcoming fifth annual Advanced Therapies Summit next ... event this year will feature five expert-led interactive ... the field’s leading companies and organizations. , ... and clinical researchers from the advanced therapies community ...
(Date:3/4/2015)... March 04, 2015 The Conrad N. ... a total of $6.9 million, which will help 151,000 ... and Burkina Faso. , The programs cover three years ... will focus on fixing water points in disrepair, addressing ... local people to maintain water points and ensuring safe ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 Nike Swim ... and staff whose mission is to stimulate a love ... “Nike Swim Camps provide campers the opportunity to train ... nation,” says Paul Merrion, Vice President of US Sports ... enabling each swimmer to build confidence and improve their ...
(Date:3/4/2015)... Nitrosigine®, a patented complex of bonded arginine ... products, is hosting the Nitrosigine Pump Challenge at the ... at The Arnold Sports Festival in Columbus, Ohio. The ... 8, 2015. , Nitrosigine is a patented ingredient ... notification status; now affirmed as GRAS.^ It has been ...
Breaking Medicine News(10 mins):Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 2Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 3Health News:The Alliance for Regenerative Medicine Announces Agenda for Upcoming Advanced Therapies Summit 2Health News:The Alliance for Regenerative Medicine Announces Agenda for Upcoming Advanced Therapies Summit 3Health News:Hilton Foundation Gives $6.9 Million to Sustainable Water Programs in West Africa 2Health News:Hilton Foundation Gives $6.9 Million to Sustainable Water Programs in West Africa 3Health News:Hilton Foundation Gives $6.9 Million to Sustainable Water Programs in West Africa 4Health News:US Sports Camps and Nike Swim Camps Announce the 2015 Swim Camps Lineup 2Health News:Nitrosigine® Challenges Fitness Enthusiasts at The Arnold to Get Pumped 2Health News:Nitrosigine® Challenges Fitness Enthusiasts at The Arnold to Get Pumped 3
... and Accelerates Physician TrainingGREAT BARRINGTON, Mass., March 17 ... surgical training models, is improving how ENT physicians ... Trainer. This innovative technology was recently designed ... on their new FinESS(TM) Sinus Treatment, a less-invasive ...
... 17 Innophos Holdings, Inc. (Nasdaq: ... declared a dividend of $0.17 per share of common stock. ... stockholders of record as of the close of business on ... , Innophos Holdings, Inc., the parent company of Innophos, Inc. ...
... the past few years, a number of anti-cancer drugs ... key molecules of tumor cells. Among these is an ... that is found in large amounts on the surface ... molecule, called epidermal growth factor receptor, or EGF-R for ...
... for Drug Evaluation and Research (CDER), industry, and academia will convene ... (April 26-29; Arlington, VA) to discuss statistical methodologies and quantitative ... , ... Horsham, PA (Vocus) March 17, 2009 -- ...
... John Hancock Life Insurance Company led the industry ... to recent industry year-end surveys of LTC insurers.* In ... across all of its LTC insurance businesses, giving the ... marks John Hancock,s second year in a row as ...
... What can you buy with a dollar anymore? ... and treatment for those who cannot afford to battle breast ... Brandon Mendelson and the 1 in 8 Foundation are challenging ... $1 and provide care and complete support for women and ...
Cached Medicine News:Health News:Chamberlain Group Surgical Training Model Facilitates New Treatment for Chronic Rhinosinusitis 2Health News:Chamberlain Group Surgical Training Model Facilitates New Treatment for Chronic Rhinosinusitis 3Health News:Innophos Holdings, Inc. Declares Quarterly Dividend 2Health News:Lung cancer: Molecular scissors determine therapy effectiveness 2Health News:Drug Information Association (DIA)and Food and Drug Administration (FDA) to Host 3rd Annual Statistics Forum 2Health News:John Hancock #1 in Long-Term Care Insurance Industry Sales in 2008 2Health News:John Hancock #1 in Long-Term Care Insurance Industry Sales in 2008 3Health News:$1 Can Make The Difference 2
MONOJECT SUPRA/HONE Blood Collection Needles - Thin Wall...
... VACUETTE Blood Collection Needles are preominantly used ... for single-use. The colour of the needle ... individual needle gauges. For example, yellow symbolises ... green 21 G (0.80 mm) and black ...
ScanGel® Centrifuge...
BIOVUE cassettes may be used manually, with a workstation consisting of a centrifuge, incubator, precision pipettes and work rack....
Medicine Products: